# STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

> **NCT05843578** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Agomab Spain S.L.U.** · enrollment: 103 (actual)

## Conditions studied

- Fibrostenotic Crohn's Disease

## Interventions

- **DRUG:** AGMB-129
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05843578
- **Lead sponsor:** Agomab Spain S.L.U.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05843578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05843578, "STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05843578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*